Citadel Advisors
CMND icon

Citadel Advisors’s Clearmind Medicine CMND Stock Holding History

Citadel Advisors’s Portfolio CMND Stock Details CMND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.8K Buy
+1,464
New +$66.7K ﹤0.01% 13342
2025
Q1 		– Sell
-12
Closed -$52.7K – 14593
2024
Q4 		$52.7K Buy
12
+6
+100% +$26.6K ﹤0.01% 12344
2024
Q3 		$21.6K Buy
+6
New +$27.3K ﹤0.01% 12720
2023
Q4 		– Hold
0
– -$2.35K – 14351
2023
Q3 		– Hold
0
– – – 13732
2023
Q2 		– Hold
0
– – – 12848
2023
Q1 		– Hold
0
– – – 13378

Other funds holding CMND

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Citadel Advisors's CMND Position: Q2 2026 in Review

Citadel Advisors opened a new position in Clearmind Medicine (CMND) in Q2 2026: 1,464 shares worth $25.8K. The stake represents ﹤0.01% of the portfolio and ranks #13342 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CMND as recently as Q4 2024.

Citadel Advisors first reported a position in CMND in Q3 2024 and has held it in 3 quarters since. The position peaked at $52.7K in Q4 2024. 5 funds tracked by Wall St. Rank hold CMND as of Q2 2026.

  • Citadel Advisors held 1,464 shares of Clearmind Medicine worth $25.8K as of Q2 2026.
  • Clearmind Medicine was a new Citadel Advisors position in Q2 2026.
  • Clearmind Medicine made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13342 holding.
  • Citadel Advisors first reported a position in Clearmind Medicine in Q3 2024 and has held it in 3 quarters since.
  • Citadel Advisors's Clearmind Medicine position peaked at $52.7K in Q4 2024.
  • 5 funds tracked by Wall St. Rank held Clearmind Medicine as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.